•  
  •  
  •  
  •  

2026-04-17 15:19:12

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Angel One Limited Reports FY26 Results: Annual Net Profit Stands at ₹9,151 Million
  • Waaree Renewable Technologies Limited Reports Explosive FY26 Results: Net Profit Doubles to ₹478 Crore
  • VST Industries Limited Reports Strong FY26 Results: Annual Net Profit Hits ₹29,086 Lakh
  • HDFC Life Insurance Reports FY26 Results: Annual Net Profit Rises to ₹1,912 Crore
  • KPI Green Energy Receives Inter-State Power Trading Licence from CERC, Enabling PanIndia Market Participation

Keywords Selected:  Tablets

Stock Report

  • Unichem Pharmaceuticals (USA) Issues Voluntary Recall of Buspirone Hydrochloride Tablets
  • Lupin Launches Dapagliflozin Tablets in the United States
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • Biocon Pharma Ltd receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg
  • Eugia Pharma receives USFDA Approval for Everolimus Tablets
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg
  • Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • NATCO receives Tentative Approval for Erdafitinib Tablets from USFDA
  • Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg
  • Lupin receives tentative approval from U.S. FDA for Siponimod Tablets
  • SMS Pharmaceutical's associate company, VKT Pharma, receives US FDA approval for its reformulated Ranitidine
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA

Latest Post

  • Angel One Limited Reports FY26 Results: Annual Net Profit Stands at ₹9,151 Million
  • Waaree Renewable Technologies Limited Reports Explosive FY26 Results: Net Profit Doubles to ₹478 Crore
  • VST Industries Limited Reports Strong FY26 Results: Annual Net Profit Hits ₹29,086 Lakh
  • HDFC Life Insurance Reports FY26 Results: Annual Net Profit Rises to ₹1,912 Crore
  • KPI Green Energy Receives Inter-State Power Trading Licence from CERC, Enabling PanIndia Market Participation


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025